Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000310763
Ethics application status
Approved
Date submitted
8/03/2013
Date registered
20/03/2013
Date last updated
16/08/2017
Type of registration
Retrospectively registered
Titles & IDs
Public title
N-Acetyl Cysteine for the Treatment of Obsessive Compulsive Disorder (OCD): A Double-Blind, Randomised, Placebo-Controlled Clinical Trial
Query!
Scientific title
N-Acetyl Cysteine for the Treatment of Obsessive Compulsive Disorder (OCD)
Query!
Secondary ID [1]
282052
0
None
Query!
Universal Trial Number (UTN)
U1111-1140-0513
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Obsessive Compulsive Disorder (OCD)
288526
0
Query!
Condition category
Condition code
Mental Health
288857
288857
0
0
Query!
Anxiety
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
N-acetyl cysteine (NAC): 500mg capsules taken orally - 1 capsule twice daily for 1 week, 2 capsules twice daily for the second week and 3 capsules twice daily (3g/day) for the remaining 13 weeks (total 16 weeks).
Query!
Intervention code [1]
286664
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo capsules taken in the same manner as the NAC, identical in appearance, which do not contain N-acetyl cysteine or any active component.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
289013
0
Severity in symptoms will be measured with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Query!
Assessment method [1]
289013
0
Query!
Timepoint [1]
289013
0
Reviewed at baseline, week 4, 8, 12 and 16
Query!
Secondary outcome [1]
301849
0
nil
Query!
Assessment method [1]
301849
0
Query!
Timepoint [1]
301849
0
nil
Query!
Eligibility
Key inclusion criteria
Fulfil DSM-IV TR diagnostic criteria for OCD
Self reported OCD will require a diagnosis from a physician
Score 16+ on the Y-BOCS at the time of recruitment
No other treatment, or be on stable treatment i.e. minimum 4 weeks of treatment or minimum of 12 weeks if a new treatment (e.g. SSRI, CBT)
Female participants of child bearing age or sexually active are required to be using effective contraception
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Known or suspected serious medical disorder i.e. cancer, organ failure
Patients undergoing current psychological programs for their OCD (a four week wash out period will be required for eligibility)
Bipolar I, schizophrenia, epilepsy
Gastrointestinal ulcers
Pregnancy or breastfeeding
History of hypersensitivity or intolerance to NAC
Patients taking 100 micrograms of selenium or 500 IU of vitamin E
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
For potential subjects, a pre screening telephone interview will be completed to assess if they meet the criteria for the trial. If so, they will be invited to meet the clinician at the Melbourne Clinic for a baseline screening interview. By signing a consent form at this interview, which outlines the nature of the trial, and meeting the criteria at the baseline interview, they will become officially enrolled in the research project. The participants will be allocated a number and then randomised into the treatment group or placebo via a computer software program. The clinician will be unaware of which group the participant will be enrolled in. A person outside the project will then code the treatments and maintain the key to this code until data collection is completed.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Subjects will be randomised into one of two groups determined by computerised random allocation using their participant number.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2 / Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
The primary efficacy analysis will assess average treatment group differences for the primary outcome measure (Y-BOCS) using a mixed-effects model, repeated measures approach (MMRM). Results from the analysis of dichotomous data (e.g. demographics data) will be presented as proportions (e.g. Relative Risks), with 95% confidence interval, and Fisher’s Exact p-value where appropriate. Non-parametric statistics will be used when assumptions for parametric methods are violated. Effect sizes will be calculated using Cohen’s d. All tests of treatment effects will be conducted using a two-sided alpha level of 0.05 and 95% confidence intervals. Data analysed via SPSS 20.0.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
27/03/2013
Query!
Actual
13/03/2013
Query!
Date of last participant enrolment
Anticipated
1/08/2014
Query!
Actual
10/12/2014
Query!
Date of last data collection
Anticipated
Query!
Actual
8/04/2015
Query!
Sample size
Target
80
Query!
Accrual to date
Query!
Final
44
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
721
0
The Melbourne Clinic - Richmond
Query!
Funding & Sponsors
Funding source category [1]
286849
0
Self funded/Unfunded
Query!
Name [1]
286849
0
Query!
Address [1]
286849
0
Query!
Country [1]
286849
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
The Melbourne Clinic
Query!
Address
130 Church St Richmond, Melbourne, Victoria, 3121
Query!
Country
Australia
Query!
Secondary sponsor category [1]
285641
0
Commercial sector/Industry
Query!
Name [1]
285641
0
Bioceuticals
Query!
Address [1]
285641
0
Unit 16 37-41 O'Riordan St,
Alexandria, NSW
2015
Query!
Country [1]
285641
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
288930
0
The Melbourne Clinic HREC
Query!
Ethics committee address [1]
288930
0
130 Church St, Richmond,
Melbourne,
VIC, 3121
Query!
Ethics committee country [1]
288930
0
Australia
Query!
Date submitted for ethics approval [1]
288930
0
Query!
Approval date [1]
288930
0
11/02/2013
Query!
Ethics approval number [1]
288930
0
219
Query!
Summary
Brief summary
The primary aim of this study is to investigate the efficacy and safety of adjunctive N-acetylcysteine (NAC) in the treatment of adults (n=80) with DSM-IV diagnosed OCD in a 16-week randomised, placebo-controlled trial. The primary outcome will be between group differences the severity of OCD symptoms on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).
Query!
Trial website
Query!
Trial related presentations / publications
N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study; Jerome Sarris, Georgina Oliver, David A. Camfield, Olivia M. Dean, Nathan Dowling, Deidre J. Smith, Jenifer Murphy, Ranjit Menon, Michael Berk, Scott Blair-West, Chee H. Ng; CNS Drugs (2015) 29: 801.
Sarris, J., Oliver, G., Camfield, D. A., & Dean, O. M. (2016). Participant characteristics as modifiers of response to N-Acetyl cysteine (NAC) in Obsessive-Compulsive Disorder. Clinical Psychological Science, 4(6), 1104-1111.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
38246
0
Dr Jerome Sarris
Query!
Address
38246
0
The Melbourne Clinic, 2 Salisbury st, Richmond, VIC, 3121
Query!
Country
38246
0
Australia
Query!
Phone
38246
0
+61404083393
Query!
Fax
38246
0
Query!
Email
38246
0
[email protected]
Query!
Contact person for public queries
Name
38247
0
Miss Gina Oliver
Query!
Address
38247
0
The Melbourne Clinic, 2 Salisbury st, Richmond, VIC, 3121
Query!
Country
38247
0
Australia
Query!
Phone
38247
0
+61 3 9487 4659
Query!
Fax
38247
0
Query!
Email
38247
0
[email protected]
Query!
Contact person for scientific queries
Name
38248
0
Miss Gina Oliver
Query!
Address
38248
0
The Melbourne Clinic, 2 Salisbury st, Richmond, VIC, 3121
Query!
Country
38248
0
Australia
Query!
Phone
38248
0
+61 3 9487 4659
Query!
Fax
38248
0
Query!
Email
38248
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
2015
https://dx.doi.org/10.1007/s40263-015-0272-9
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF